- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05802329
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME) (DME)
A Phase 1 Study To Assess The Safety And Efficacy Of OCU200 For Center-Involved Diabetic Macular Edema
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a multicenter, open-label, dose ranging study with 3 cohorts in the dose-escalation portion of the study and 1 cohort in the combination therapy portion of the study. An accelerated 3+3 design with parallel and sequential dosing will be used.
A total of 9 to 22 participants will be enrolled in the dose-escalation portion of the study to receive OCU200 alone (9 to 18 participants enrolled according to the 3+3 design and up to 4 participants replaced due to parallel cohort initiation). For the combination therapy cohort, a total of 3 to 6 participants will be enrolled to receive OCU200 (MTD) + Lucentis.
A total of up to 28 participants will be included in this study.
The following algorithm will be followed for dose-escalation:
Cohort 1 Low Dose (0.5 mg/mL): 3+3 participants will receive intravitreal injection of OCU200 low dose concentration.
1 of 3 results will occur from the first 3 Cohort 3 participants (first dose):
- If none of the first 3 participants on high dose concentration are determined by the DSMB to have a DLT, then the high dose concentration will be the determined MTD.
- If 2 or more of the first 3 participants on the high dose concentration are determined by the DSMB to have a DLT, then the medium dose concentration (1 mg/mL) will be the determined MTD. Any dosing on Cohort 4 will be paused and continuation will be re-assessed.
If exactly 1 of the first 3 participants on high dose concentration is determined by the DSMB to have a DLT, then 3 additional participants will be enrolled on high dose concentration. Any dosing on Cohort 4 will be paused and continuation will be reassessed.
- If none of the 3 additional participants are determined by the DSMB to have a DLT, then the high dose concentration will be the determined MTD.
- If 1 or more of the 3 additional participants are determined by the DSMB to have a DLT, then the medium dose concentration will be the determined MTD. Upon positive DSMB recommendation following dose 1, participants will subsequently receive a 2nd dose (6 weeks later) according to their assigned cohort. The DSMB will review 2 weeks of safety data post 2nd dosing. If a DLT occurs after the 2nd dose of any subject, the dosing interval or dose concentration will be re-assessed.
The following algorithm will be followed for combination therapy cohort:
Cohort 4 MTD + Lucentis: 3 + 3 additional participants will be enrolled to receive OCU200 (High Dose or MTD) + Lucentis (in a sequential manner on dosing dates).
The sentinel participant in Cohort 4 will only be dosed after DSMB review of safety data for the sentinel subject in Cohort 3 or the determination of OCU200 MTD.
If the sentinel participant does not have a DLT as determined by DSMB, two additional participants will be dosed. The DSMB will continue to review all available safety data two weeks post dosing of participants.
Cohort 2 Medium Dose (1 mg/mL): 3+3 participants will receive intravitreal injection of OCU200 medium dose concentration. Following the same algorithm as Cohort 1.
Cohort 3 High Dose (2 mg/mL): 3+3 participants will receive intravitreal injection of OCU200 high dose concentration. Following the same algorithm as Cohort 2.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Brad Stefanovic, PhD
- Phone Number: 6465103437
- Email: brad.stefanovic@ocugen.com
Study Contact Backup
- Name: Shane Spence
- Phone Number: 484-237-3384
- Email: shane.spence@ocugen.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1. Diagnosis of Type 1 or Type 2 Diabetes Mellitus 2. Decreased visual acuity attributable primarily to DME 3. Central-involved DME with central retinal subfield thickness (CST) values, as assessed with spectral-domain optical coherence tomography (SD-OCT) of:
- ≥ 320 if male or ≥ 305 µm if female on Heidelberg Spectralis
- ≥ 305 if male or ≥ 290 if female on Zeiss Cirrus
- BCVA ≤ 78 and ≥ 24 letters on ETDRS chart (approximately 20/32 to 20/320 Snellen equivalents, respectively) in the study eye.
- Sufficient ocular media clarity, pupillary dilation and participant cooperation to permit acquisition of good quality retinal imaging
- No history of prior anti-VEGF injection for treatment of DME or history of at least 2 consecutive anti-VEGF intravitreal injection (less than 7 weeks apart) for the treatment of DME with documented incomplete resolution of central subfield thickening within 1 year prior to the screening visit. The last injection should be within 3 months prior to the screening visit.
Exclusion Criteria:
- Presence of any condition that prevent clear visualization of retina (e.g., significant cataract, vitreous hemorrhage)
- Uncontrolled hypertension (systolic pressure above 180 mmHg or diastolic pressure above 110 mmHg)
- Uncontrolled glaucoma
- Concurrent disease in the study eye, other than central-involved DME, that could compromise BCVA, require medical or surgical intervention during the study period or could confound interpretation of the results
- Intravitreal or periocular steroid treatment within 3 months prior to the screening visit or fluocinolone acetonide implant (Iluvien®) within 36 months prior to screening visit or dexamethasone implant (Ozurdex®) within 6 months prior to the screening visit.
- Any ocular surgery within 3 months prior to the screening visit in the study eye (e.g., cataract surgery, corneal refractive surgery)
- Prior vitrectomy in the study eye
- Uncontrolled/poorly controlled diabetes, as defined by Glycated hemoglobin (HbA1c) ≥ 12%
- History of retinal detachment in the study eye
- History of any other retinal vascular disease in the study eye including conditions that affect macular perfusion (e.g., retinal artery occlusion, retinal vein occlusion, vasculitis)
- Focal or pan-retinal laser photocoagulation in the study eye within 3 months prior to the screening visit
- Presence of any inherited retinal disease (e.g., chorioretinal dystrophies, rod/cone dystrophies)Any proliferative diabetic retinopathy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1 (Low Dose)
3+3 participants will receive intravitreal injection of OCU200 low dose concentration.
|
Intravitreal Injection
Other Names:
|
Experimental: Cohort 2 (Medium Dose)
3+3 participants will receive intravitreal injection of OCU200 medium dose concentration.
|
Intravitreal Injection
Other Names:
|
Experimental: Cohort 3 (High Dose)
3+3 participants will receive intravitreal injection of OCU200 high dose concentration.
|
Intravitreal Injection
Other Names:
|
Experimental: Cohort 4 (High Dose/MTD + Lucentis)
3 + 3 additional participants will be enrolled to receive OCU200 (High Dose or MTD) + Lucentis (in a sequential manner on dosing dates).
|
Intravitreal Injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Study Drug-related adverse events (SDAE)
Time Frame: 20 weeks
|
Counts, frequencies and percentages of SDAEs.
|
20 weeks
|
treatment-emergent adverse events (TEAEs)
Time Frame: 20 weeks
|
Counts, frequencies and percentages TEAEs.
TEAEs are defined as an event that was not present prior to administration of the dose of study drug and present after the dose, or if it represents the exacerbation of an event that was present prior to the dose.
|
20 weeks
|
serious adverse events (SAEs)
Time Frame: 20 weeks
|
Counts, frequencies and percentages of SAEs including Resulted in Death, Life-threatening, Hospitalization, Disabling/incapacitating, Congenital anomaly or birth defect and Medically significant AEs ( AE that did not meet any of the above criteria but could have jeopardized the subject and might have required medical or surgical intervention to prevent one of the outcomes listed above).
|
20 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best-corrected visual acuity (BCVA)
Time Frame: 20 Weeks (Changes from baseline)
|
Measured as the ETDRS letter score on the EVA tester or E-ETDRS charts.
|
20 Weeks (Changes from baseline)
|
Intraocular pressure (IOP)
Time Frame: 20 weeks(Changes from baseline)
|
IOP measurement by applanation or rebound tonometry.
Confirmation with Goldmann tonometer if IOP reading is outside the normal range (8-21mmHg).
|
20 weeks(Changes from baseline)
|
Slit-lamp biomicroscopy
Time Frame: 20 Weeks(Changes from baseline)
|
Changes in visual function.
|
20 Weeks(Changes from baseline)
|
Indirect ophthalmoscopy
Time Frame: 20 Weeks (Changes from baseline)
|
If visual acuity is so poor that the participant is unable to count fingers or perceive hand motion, light perception will be tested with the indirect ophthalmoscope as the light source.
|
20 Weeks (Changes from baseline)
|
Color fundus photography
Time Frame: 20 Weeks(Changes from baseline)
|
Color fundus photographs will be taken to evaluate retinal anatomy and grade diabetic retinopathy severity scale (DRSS).
|
20 Weeks(Changes from baseline)
|
Spectral Domain Optical Coherence Tomography (SD-OCT)
Time Frame: 20 Weeks(Changes from baseline)
|
SD-OCT will be utilized to assess retinal thickness.
OCT images and scans will be transmitted to a central reading center for independent analysis.
|
20 Weeks(Changes from baseline)
|
Spectral Domain Optical Coherence Tomography Angiography (SD-OCTA)
Time Frame: 20 weeks (Changes from baseline)
|
SD-OCTA will be utilized to assess retinal vasculature and images will be transmitted to a central reader for independent analysis.
|
20 weeks (Changes from baseline)
|
Wide-field Fluorescein Angiography (wf-FA)
Time Frame: 20 weeks (Changes from baseline)
|
wf-FA will be conducted at screening and EOS visits to assess central and peripheral vasculature.
|
20 weeks (Changes from baseline)
|
Anti-OCU200 antibody formation
Time Frame: 20 weeks
|
Blood samples will be collected for the assessment.
|
20 weeks
|
OCU200 Pharmacokinetics parameters
Time Frame: 20 weeks
|
Blood samples will be collected for the assessment.
|
20 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement of diabetic retinopathy severity scale (DRSS)
Time Frame: 20 weeks
|
Proportion of participants with ≥ 2-step improvement of diabetic retinopathy severity scale (DRSS)
|
20 weeks
|
Change from baseline in BCVA letters.
Time Frame: 20 weeks
|
Dose response as assessed by mean change from baseline in BCVA letters using ETDRS chart and mean number of injections by study visit
|
20 weeks
|
Changes in CST.
Time Frame: 20 weeks
|
Changes from baseline in CST on SD-OCT exam
|
20 weeks
|
Best Corrected Visual Acuity
Time Frame: 20 Weeks
|
Changes from baseline in BCVA measured by ETDRS chart
|
20 Weeks
|
Reduction of CST
Time Frame: 20 Weeks
|
The proportion of participants having a ≥ 10% reduction of CST at Week 13 and Week 19
|
20 Weeks
|
mean increase ≥ 5 BCVA letters
Time Frame: 20 Weeks
|
The proportion of participants having a mean increase ≥ 5 BCVA letters at Week 13 and Week 19
|
20 Weeks
|
Requirement of rescue intervention
Time Frame: 20 weeks
|
The proportion of participants who require rescue intervention
|
20 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Roshan George, MD, Ocugen
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OCU200-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Macular Edema
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletedDiabetic Macular Edema | Cystoid Macular EdemaUnited States
-
OculisICON plcRecruitingDiabetic Macular EdemaUnited States
-
Novartis PharmaceuticalsNot yet recruiting
-
Vista KlinikNot yet recruitingDiabetic Macular Edema
-
Chinese University of Hong KongRecruiting
-
Laboratorios Sophia S.A de C.V.RecruitingDiabetic Macular EdemaColombia, Mexico
-
Centre Hospitalier Universitaire DijonRecruiting
-
Uptown Eye SpecialistsNot yet recruitingDiabetic Macular Edema
-
Hospices Civils de LyonRecruiting
-
Hoffmann-La RocheCompletedDiabetic Macular EdemaUnited States, Korea, Republic of, United Kingdom, Brazil, Japan, Canada, Argentina, Australia, Austria, Denmark, France, Germany, Hungary, Italy, Poland, Slovakia, Spain, Singapore, Czechia, Hong Kong, Israel, Portugal, Russian Federation and more
Clinical Trials on OCU200 Low Dose
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedPneumonia | Coronavirus Infection in 2019 (COVID-19) | Severe Acute Respiratory Syndrome (SARS) PneumoniaUnited States
-
MedImmune LLCCompletedNon-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)United States, Puerto Rico
-
Beijing Northland Biotech. Co., Ltd.CompletedSafety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.InfarctionAcute Myocardial InfarctionChina
-
Lucozade Ribena SuntoryKing's College LondonCompletedPostprandial PeriodUnited Kingdom
-
Indonesia UniversityMedika Natura Sdn BhdCompleted
-
Yiling Pharmaceutical Inc.CompletedPharmacokinetics | Healthy Adult Subjects | Safety and TolerabilityUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingLung CarcinomaUnited States
-
Postgraduate Institute of Medical Education and...Completed
-
Spectrum DynamicsBrigham and Women's Hospital; Cedars-Sinai Medical Center; Oregon Heart and Vascular...Completed